Conference | RheumNow

Oct 25-29, 2025

Topics

What's hot

View all perspectives

What's Hot

The Great Debate: AI in Rheumatology

Drs. Mrinalini Dey, Jeffrey Curtis and Jinoos Yazdany

Watch video →

RA: Inject the Steroids

Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the 2025 ACR Convergence meeting in Chicago.

Watch video →

ACR2025 CAR-T Topic Panel

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping CAR-T practice right now. Panelists: Drs. Al Kim, Philip Mease, Yuz Yusof, Akhil Sood, and Jack Cush.

Watch video →

Tapering in SELECT GCA: Steroids are the Problem

Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at the 2025 ACR Convergence meeting in Chicago.

Watch video →

Specialized Biomarkers in PsA

Dr. Elaine Husni reports on abstract 0111 (Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures).

Watch video →

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA

At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.

Day 4 Recap: ACR Convergence 2025 Highlights

Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.

Watch video →

Weight Loss as a Therapeutic Goal in Psoriatic Arthritis

Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.

ACR 2025 - Day 3 Report

Day 3 in Chicago is hump day, the last big full day of presentations and posters. The day began with an 8AM plenary session, which brings me to the first of my three notables from today:

The Great Debate – Who Really Won?

My favorite session at ACR Convergence is often the “Great Debate.” The debate this year also evaluated one of my favorite topics – ultrasound in giant cell arteritis (GCA). More specifically, it asked the question of whether biopsy or ultrasound should be the preferred modality for diagnosing GCA.

What's the latest in PsA?

Dr. Peter Nash highlights key studies presented at the 2025 ACR Convergence meeting.

Watch video →

Is it All About the Weight Loss?

Dr. Jeffrey Curtis discusses two abstracts about the use of GLP-1 drugs and their impact beyond weight loss.

Watch video →

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.